Grantclosed🌐 United StatesRFA-DA-24-007

Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)

National Institutes of Health

Details?

Posted: Oct 20, 2022
Response deadline: Aug 7, 2025, 12:00 AM UTC
Type: Grant
Category: 93.279
Status: closed
Buyer: National Institutes of Health
Department: HHS-NIH11
Jurisdiction: United States
Reference #: RFA-DA-24-007

Doc Type: synopsis
Opp Status: archived

Similar past solicitations

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)
United States · Oct 21, 2022
Avenir Award Program for Research on Substance Use Disorders and HIV (DP2 Clinical Trial Optional)
United States · Mar 10, 2023
NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
United States · Nov 21, 2024
Dynamic and Adaptable Infrastructure for Drug Development and Outreach to Aid the Research Community in Advancing Medication Repurposing and Repositioning Efforts for Substance Use Disorders (SUDs) (U54 - Clinical Trials Not Allowed)
United States · Sep 24, 2025
Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
United States · Sep 9, 2024
Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
United States · Aug 23, 2024

Finding similar opportunities…

This listing is a summary from United States's open procurement data. We ingest every field the feed publishes; the full solicitation documents are on the source portal.